Teoxane has announced that at AMWC Monaco 2026, they will introduce MLT 3.1 - a multi-level holistic protocol described by the brand as a comprehensive response to facial changes following rapid weight loss. The focus of the announcement is not on a specific area or product, but on a holistic strategy involving structural support, volume restoration, and skin quality improvement.
In their release, the company directly links this topic to the new metabolic reality where incretin therapies accelerate weight loss, leading to noticeable changes in facial tissues. Teoxane emphasizes that in such cases, it's not just about a slimmer face but deeper anatomical and dermal changes that require a different logic of aesthetic correction.
According to the brand, rapid weight loss can lead to a reduction in superficial and deep fat compartments, decreased projection and structural support, and enhanced shadowing in the tear trough, temples, and mid-face areas. The company also highlights issues like sagging, dullness, texture changes, reduced elasticity, and disrupted skin hydration balance. Therefore, Teoxane presents this issue as a combination of volume loss and skin quality deterioration, rather than typical age-related aging.
In this context, MLT 3.1 is presented as an anatomically oriented approach that moves away from isolated corrections to a multi-level, more coordinated facial optimization. The company describes it as a combination of deep support, targeted volume restoration, and dermal optimization to address not only contours but also how the skin looks, feels, and behaves after rapid weight loss. More about the role of hyaluronic acid in such approaches can be read in a separate Cosmet.Info publication.
What will Teoxane showcase at AMWC 2026?
As part of their scientific presence at the congress, the brand announced a symposium dedicated to facial changes after rapid weight loss, along with two scientific posters. The first poster addresses facial changes after rapid weight loss associated with incretin mimetics, while the second focuses on facial lipoatrophy associated with antiretroviral therapy. In their communication, Teoxane unites these two clinical contexts as related examples of medically induced volume loss, reinforcing the argument for a comprehensive, anatomically oriented approach.
The release also emphasizes that rapid weight loss particularly affects the under-eye area, temples, and mid-face, where a sharp reduction in superficial fat compartments leads to hollowing, increased shadowing, and changes in the overall perception of the face. According to the company, the combination of support loss, volume change, and dermal depletion creates a clinical scenario that requires not a pinpoint correction but a balanced approach to volume redistribution and skin quality improvement.
Teoxane also highlights that patients often expect body changes but do not always anticipate how rapid weight loss will affect their face. This discrepancy between expected results and actual appearance transformation is one of the reasons the brand is dedicating a separate scientific-educational block to this topic at AMWC 2026.
“We are entering a metabolic era, and the rapid spread of weight loss therapies has created a new aesthetic phenotype - with volume shifts, skin quality changes, and different facial dynamics. Neither patients nor practitioners were fully prepared for such acceleration. Our task is to develop clear approaches and practical guidelines to help doctors safely and predictably work with facial changes after rapid weight loss.”
Dr. Mounia Heddad-Masson, PhD, Director Global Medical Education & Medical Affairs at Teoxane
What does MLT 3.1 mean in the brand's presentation?
In Teoxane's presentation, MLT 3.1 is not just a technique name but a branded multi-level approach to facial optimization. The company describes it as a tool that allows combining deep structural support, volume deficit correction, and work with dermal characteristics in one coordinated solution. Among the expected results, the brand mentions a more natural and harmonious appearance, preservation of individual facial features, and improved hydration, density, texture, and skin radiance.
At the same time, for a news format, it is important to note that this is specifically a branded Teoxane protocol, which the company promotes through its scientific and educational platform. Thus, MLT 3.1 is presented not as a universal independent standard for all clinical situations but as the brand's proprietary approach to the new wave of requests in aesthetic medicine.
Why is this announcement important for the market?
The news is significant not only as a corporate release but also as a marker that the topic of facial changes after rapid weight loss is transitioning into a stable professional discussion. Previously, the market often talked separately about volume loss or products to improve skin quality, but now brands are increasingly framing the problem more broadly - as a change in multiple tissue layers simultaneously, requiring a combined tactic.
For doctors, this means growing interest in patients whose contours, light-shadow balance, skin quality, and overall tired visual characteristics of the face change after rapid weight loss. For the market of products and techniques, this means a further shift towards protocol communication, where the brand promotes not only the product but also the full logic of its application in a specific clinical scenario.
Against this backdrop, Teoxane's announcement appears as an attempt to establish itself in one of the key topics of modern injectable aesthetics - facial correction after rapid metabolic weight loss through multi-level, anatomically precise, and more cautious work with tissues. More about the risks and limits of such solutions can be read in the material about the safety of hyaluronic acid-based fillers.
AMWC Monaco 2026 took place from March 26-28 in Monaco, and Teoxane's participation in the congress's scientific program shows that the topic of facial changes after rapid weight loss is already establishing itself as a separate direction of professional conversation in aesthetic medicine.
About the brand
Teoxane is an international aesthetic medicine brand headquartered in Geneva, operating in the segment of injectable solutions and hyaluronic acid-based products. The company regularly participates in specialized international congresses and develops its own protocols and educational formats for aesthetic medicine professionals.
